Finding new treatment targets in metastatic stomach cancer
Official title: Identification of Novel Therapeutic Targets in Gastric Cancer With Lymph Node or Distant Metastasis: An Explorative Study
Run by Chinese University of Hong Kong · NCT07551440 · Data updated 2026-11-12
This pilot project will try to find molecular targets in adults with metastatic stomach cancer to help guide future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | October 15, 2023 |
| Main results expected | April 2033 |
| Study ends | October 2033 |
| Registry record updated | April 24, 2026 |
| Trial ID | NCT07551440 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–80 years old with gastric adenocarcinoma and lymph node or distant metastases, WHO performance status ≤2, who will receive neoadjuvant or palliative systemic therapy and can consent are ideal candidates.
✕Probably not a fit
People who will not receive neoadjuvant or palliative systemic therapy, who are pregnant or breastfeeding, or who have irreversible coagulation disorders are unlikely to participate or benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center pilot observational project at the Prince of Wales Hospital that will screen adults diagnosed with gastric adenocarcinoma that has spread to lymph nodes or distant sites. Enrolled patients who are scheduled for neoadjuvant or palliative chemotherapy, targeted therapy, or immunotherapy will have tumor samples and clinical data collected. The samples will undergo molecular profiling to identify potential therapeutic targets. The goal is to generate candidate targets that can be tested in later clinical trials.
Why it matters
Potential benefit: If successful, the study could reveal new molecular targets that lead to more effective, personalized treatments for metastatic stomach cancer.
How similar studies have gone: Previous molecular profiling in gastric cancer has identified actionable markers such as HER2 amplification, MSI status, and PD-L1 expression, supporting this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients age \>= 18, \<= 80 years old 2. Performance status (WHO) \<=2 3. Gastric adenocarcinoma with lymph node metastasis or distant metastasis such as liver metastases, lung metastases, bone metastases, peritoneum metastases 4. Patients with isolated ovarian metastasis could be included 5. Patients who will be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy 6. Ability to give written consent before the commencement of treatment Exclusion Criteria: 1. Patient who will not be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy 2. Pregnancy or breastfeeding 3. Patients with irreversible coagulation disorders
Where it's running
-
The Chinese University of Hong Kong
Hong Kong, Hong Kong Recruiting
Study contacts
- Study coordinator: Shannon Melissa Chan, PhD
- Email: shannonchan@surgery.cuhk.edu.hk
- Phone: 35052627
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Candonilimab with Fruquintinib and Paclitaxel Albumin-Bound as second-line treatment for advanced gastric cancer
This phase 2 trial tests whether adding candonilimab to fruquintinib and nab-paclitaxel helps people with advanced gastric or gastroesophageal junction cancer who progressed after first-line therapy.
-
TEAS after gastrectomy to aid recovery after laparoscopic stomach cancer surgery
A randomized trial tests whether transcutaneous electrical acupoint stimulation (TEAS) after laparoscopic gastrectomy helps people recover faster and with less pain compared with a sham treatment.
-
Maintenance therapy in metastatic gastric cancer: a multicenter look from Colombia
This study reviews medical records of adults with metastatic gastric cancer in Colombia to see how patients fare after starting maintenance therapy following initial chemotherapy.
-
Stomach-Partitioning Surgery to Help Block Obstruction in Advanced Stomach Cancer
This trial tests whether stomach-partitioning gastrojejunostomy helps people with unresectable, advanced stomach cancer better tolerate food after surgery than the standard approach.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
TEAS timing to aid recovery after stomach cancer surgery
This trial tests whether transcutaneous electrical acupoint stimulation (TEAS) given around surgery helps people recover faster after laparoscopic gastrectomy for gastric cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.